We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s sales revenue dipped 5 percent in the U.S. and 2 percent worldwide during the third quarter — a decline caused largely by the withdrawal of its painkiller Vioxx and slumping sales of its blockbuster cholesterol-lowering drug Zocor.